Anti-GBM Autoantibody Disease Market
Number of pages: 100 | Report Format: PDF | Published date: May 05, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
4.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment Type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Anti-GBM autoantibody disease market is expected to register a revenue CAGR of 4.3% during the forecast period of 2023-2031
Anti-GBM autoantibody disease Market Fundamentals
Anti-GBM disease is an autoimmune condition. It happens when the immune system mistakenly targets and kills healthy bodily tissue. People with this disease produce chemicals that assault a protein called collagen in the lungs' small air sacs and the kidneys' filtering units (glomeruli). In the Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, the condition is classified as immune-complex small vessel vasculitis. The clinical condition comprises a continuum of renal involvement ranging from minimal to no renal involvement to rapidly increasing glomerulonephritis. Many patients experience pulmonary hemorrhage, and most people show signs of a generalized systemic illness. The combination of glomerulonephritis and pulmonary bleeding is known as Goodpasture syndrome. However, some clinicians may use several terms interchangeably, such as anti-glomerular basement membrane disease, Goodpasture syndrome, and Goodpasture disease. The most precise phrase for anti-GBM illness is the presence of renal and pulmonary involvement and anti-glomerular basement membrane antibodies. The illness might manifest traditionally or as glomerulonephritis alone. Goodpasture syndrome is an uncommon condition. In Asian and European populations, the incidence of anti-GBM disease ranges from 0.5 to 1.8 cases per million per year. It is the cause of 1-5% of all glomerulonephritides. Furthermore, it accounts for 10% to 20% of crescentic glomerulonephritis.
The research study on the Anti-GBM autoantibody disease market overview thoroughly analyzes the market, along with the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion. The research also analyses how the COVID-19 pandemic has affected society.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth Anti-GBM autoantibody disease market forecast to the industry stakeholders.
Anti-GBM Autoantibody Disease Market Dynamics
The rising incidence of unhealthy lifestyles and an aging population are the primary factors driving the worldwide Anti-GBM autoantibody disease market. Other factors driving the growth of the global Anti-GBM autoantibody disease market include the use of hair dyes, tobacco use, and exposure to hydrocarbons, among others. Furthermore, an increase in the number of clinical trials, robust R&D, and increased awareness in developed countries are expected to drive the growth of the Anti-GBM autoantibody disease market. According to the National Organization for Rare Disorders, males are more commonly affected than females by Goodpasture syndrome. Around 600 cases of Goodpasture syndrome are already documented in the medical literature. According to the Clinical Kidney Journal, Goodpasture syndrome affects one in a million persons annually.
However, stringent regulations and diagnostic challenges are expected to hinder the growth of the global Anti-GBM autoantibody disease market during the forecast period.
Anti-GBM autoantibody disease Market Ecosystem
Anti-GBM autoantibody disease Market, by Treatment Type
Anti-GBM autoantibody disease Market, by Distribution Channel
Anti-GBM autoantibody disease Market by Treatment Type
[654321]
The Immunosuppressive segment is likely to dominate the market during the forecast period. Regardless of renal status, all patients with pulmonary symptoms should commence combination therapy. The dangers of plasmapheresis and immunosuppressive treatment may outweigh the advantages for patients who do not have pulmonary symptoms and whose renal recovery is very dubious (i.e., those who arrived with an urgent need for dialysis within the first 72 hours). Because the disease has yet to be thoroughly studied in controlled trials, the decision to discontinue treatment in these cases is debatable. It is still unclear who in this group will react and restore renal function.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as treatment type and distribution channel. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential Anti-GBM autoantibody disease market growth opportunities.
Anti-GBM autoantibody disease Market by Region
Because of the increasing unhealthy lifestyle and drug misuse, North America is expected to be the major market in the worldwide Anti-GBM autoantibody disease market.
Due to increasing awareness of health-related issues, Europe will likely have the second-largest share of the worldwide Anti-GBM autoantibody disease market throughout the forecast period. The Asia Pacific, excluding Japan’s Anti-GBM autoantibody disease market, is predicted to develop rapidly at a considerable CAGR, owing mostly to the growing elderly population and increased healthcare facilities.
Based on the regions, the global Anti-GBM autoantibody disease market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding the Anti-GBM autoantibody disease market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
Anti-GBM Autoantibody Disease Market Competitive Landscape
Some of the prominent market players in the global Anti-GBM autoantibody disease market include,
The global Anti-GBM autoantibody disease market is highly concentrated, with a few competitors controlling a sizable portion of the industry. The industry's top companies are making significant efforts to preserve their market leadership by concentrating on research and development activities. Furthermore, the growing emphasis on technological advancements and innovations is expected to generate potential growth opportunities for market participants in the coming years.
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats keeping in mind the Anti-GBM autoantibody disease industry trends.
Anti-GBM autoantibody disease Market Strategic Developments
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
Anti-GBM disease is an autoimmune condition. It happens when the immune system mistakenly targets and kills healthy bodily tissue. People with this disease produce chemicals that assault a protein called collagen in the lungs' small air sacs and the kidneys' filtering units (glomeruli).
North America region/country will have the largest Anti-GBM autoantibody disease market size during the forecast period from 2023 to 2031.
The revenue CAGR in the global Anti-GBM autoantibody disease market is expected to have around 4.3%.
The industry's top companies are making significant efforts to preserve their market leadership by concentrating on research and development activities.
The rising incidence of unhealthy lifestyles and an aging population are the primary factors driving the market.
Some prominent global Anti-GBM autoantibody disease market players include Asahi Kasei Medical Co., Ltd., AbbVie, Inc., and B. Braun Melsungen AG.
The immunosuppressive segment has the highest share in the global Anti-GBM autoantibody disease market.
*Insights on financial performance are subject to the availability of information in the public domain